SENORES: No Deviation in Fund Utilization for Q4FY26 Preferential Issue
Senores Pharmaceuticals confirms no deviation in fund utilization for its ₹95 crore preferential issue of warrants for the quarter ended March 31, 2026. Funds were raised on March 28, 2026. The statement was approved by the Audit Committee and Board on May 14, 2026.
This is a standard compliance filing and does not introduce new information that would significantly impact the company's valuation or operations.
The announcement is a routine regulatory filing confirming no deviations in fund utilization, which is a neutral event.
Senores Pharmaceuticals Limited has submitted its statement of deviation(s) or variation(s) in the utilization of funds raised through a preferential issue of 11,70,000 convertible equity warrants. The funds, amounting to ₹95,00,40,000, were raised on March 28, 2026, through warrants convertible into equity shares at an exercise price of ₹812 each.
For the quarter ended March 31, 2026, the company confirms that there have been no deviations or variations in the utilization of these funds for the objects stated in the explanatory statement of the Extra-ordinary General Meeting held on January 31, 2026. The statement was reviewed by the Audit Committee and taken on record by the Board of Directors on May 14, 2026.
Specifically, funds allocated for working capital requirements (₹31,25,30,000) saw ₹2,50,00,000 utilized this quarter with no deviation. Product development expenditure (₹25,00,00,000) and investment in subsidiaries for working capital (₹15,00,00,000) also reported no deviation, with nil and ₹2,50,00,000 utilized respectively. The general corporate purpose allocation of ₹23,75,10,000 had nil utilization and no deviation reported for the quarter. The total utilization for the quarter amounted to ₹5,00,00,000.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.